Thomas Knudsen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Thomas Knudsen has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Analeise Guild
Global Gastroschisis Foundation, USA
3 shared publications - Andrea Gilbaugh
Clinical Nutrition, Stanford Medicine Children's Health, Palo Alto, California, USA
3 shared publications - James Thomas Brenna
University of Texas at Austin, USA
3 shared publications - John Kerner
Division of Gastroenterology, Hepatology, and Nutrition and Division of Neonatology and Developmental Medicine, Stanford University Medical Center, Palo Alto CA, USA
3 shared publications - Michael I. Goran
Division of Endocrinology, Diabetes and Metabolism, Department of Pediatrics Children's Hospital Los Angeles Los Angeles California USA
3 shared publications - Nan Du
Division of Gastroenterology, Hepatology and Nutrition Boston Children's Hospital Boston Massachusetts USA
3 shared publications
Latest Publications
- Open Access
- 5 August 2025
- Published by MDPI AG in Preprints.org
FDA Expert Panel on Infant Formula “Operation Stork Speed” June 2025: Part 2, Regulatory and Safety Considerations
Operation Stork Speed was launched to modernize infant formula oversight after 2022 shortages and other evidence of supply chain and safety issues. Current Food and Drug Administration(FDA) processes to regulate formula are at times slow and complex, making it difficult for new formulas to enter the market. One key pathway to adding bioactive substances or other compounds to infant formula is via the Generally Recognized as Safe (GRAS) route. GRAS and food additive pathways require safety data, but food additive petitions require more safety information and cannot be marketed until FDA approval is granted. Concern has been expressed about the safety of formula related to the possible presence of toxic substances in formula. Heavy metals, PFAS and other toxins can be found in formulas and infants can be at increased risk of effects. US lacks enforceable limits, unlike EU, Canadian and Australian counterparts. To enhance the regulatory environment for infant formula, legislative updates, supply chain transparency and alignment with global safety standards are needed.
- 5 August 2025
- Published by MDPI AG in Preprints.org
Open AccessFDA Expert Panel on Infant Formula “Operation Stork Speed” June 2025: Part 2, Regulatory and Safety Considerations
Operation Stork Speed was launched to modernize infant formula oversight after 2022 shortages and other evidence of supply chain and safety issues. Current Food and Drug Administration(FDA) processes to regulate formula are at times slow and complex, making it difficult for new formulas to enter the market. One key pathway to adding bioactive substances or other compounds to infant formula is via the Generally Recognized as Safe (GRAS) route. GRAS and food additive pathways require safety data, but food additive petitions require more safety information and cannot be marketed until FDA approval is granted. Concern has been expressed about the safety of formula related to the possible presence of toxic substances in formula. Heavy metals, PFAS and other toxins can be found in formulas and infants can be at increased risk of effects. US lacks enforceable limits, unlike EU, Canadian and Australian counterparts. To enhance the regulatory environment for infant formula, legislative updates, supply chain transparency and alignment with global safety standards are needed.
- Open Access
- 4 August 2025
- Published by MDPI AG in Preprints.org
FDA Expert Panel on Infant Formula “Operation Stork Speed” June 2025: Part 3, Marketing of Infant Formulas, Breastfeeding Support, Hypoallergenic Formulas, and Nutrition for Preterm Infants
The U.S. formula industry utilizes aggressive marketing strategies which exploit parental anxieties, undermine breastfeeding, violate ethical international standards, all of which contribute to early formula introduction and disparities in breastfeeding. Additionally, misleading or complex labeling contribute to caregiver and provider confusion regarding the content of formulas. A centralized, Food and Drug Administration (FDA)-maintained database of infant formulas could support caregivers and healthcare professionals in countering misinformation and making evidence-based decisions. Human milk remains the gold standard for infant nutrition, with strong evidence supporting its role in reducing morbidity and mortality, especially in the Neonatal Intensive Care Unit (NICU). Despite this, disparities persist in breastfeeding rates, particularly among Black and Hispanic mothers. These are driven by structural barriers, including lack of paid parental leave and inadequate lactation support. Donor human milk (DHM) is the recommended alternative for high-risk infants in the NICU when mother’s own milk (MOM) is unavailable. However, due to lack of federal funding and oversight, high cost and inconsistent insurance coverage, the use of DHM use is limited, especially in safety-net hospitals. Specialized hypoallergenic and metabolic formulas are essential for managing medical conditions including cow’s milk-protein allergy and inborn errors of metabolism. These are regulated as exempt formulas but must meet rigorous clinical standards. In the NICU, adequate early nutrition for preterm infants is crucial to reduce morbidity and mortality and improve long-term neurodevelopmental outcomes. Human milk fortifiers (HMFs) are composed of similar ingredients as infant formula and are used to improve the nutritional content feedings given in the NICU and post-discharge. The use of live biotherapeutic products (LBPs) or probiotics as additives to preterm infants have been demonstrated in multiple studies to reduce the incidence of NEC, late-onset sepsis, and all-cause mortality.
- 4 August 2025
- Published by MDPI AG in Preprints.org
Open AccessFDA Expert Panel on Infant Formula “Operation Stork Speed” June 2025: Part 3, Marketing of Infant Formulas, Breastfeeding Support, Hypoallergenic Formulas, and Nutrition for Preterm Infants
The U.S. formula industry utilizes aggressive marketing strategies which exploit parental anxieties, undermine breastfeeding, violate ethical international standards, all of which contribute to early formula introduction and disparities in breastfeeding. Additionally, misleading or complex labeling contribute to caregiver and provider confusion regarding the content of formulas. A centralized, Food and Drug Administration (FDA)-maintained database of infant formulas could support caregivers and healthcare professionals in countering misinformation and making evidence-based decisions. Human milk remains the gold standard for infant nutrition, with strong evidence supporting its role in reducing morbidity and mortality, especially in the Neonatal Intensive Care Unit (NICU). Despite this, disparities persist in breastfeeding rates, particularly among Black and Hispanic mothers. These are driven by structural barriers, including lack of paid parental leave and inadequate lactation support. Donor human milk (DHM) is the recommended alternative for high-risk infants in the NICU when mother’s own milk (MOM) is unavailable. However, due to lack of federal funding and oversight, high cost and inconsistent insurance coverage, the use of DHM use is limited, especially in safety-net hospitals. Specialized hypoallergenic and metabolic formulas are essential for managing medical conditions including cow’s milk-protein allergy and inborn errors of metabolism. These are regulated as exempt formulas but must meet rigorous clinical standards. In the NICU, adequate early nutrition for preterm infants is crucial to reduce morbidity and mortality and improve long-term neurodevelopmental outcomes. Human milk fortifiers (HMFs) are composed of similar ingredients as infant formula and are used to improve the nutritional content feedings given in the NICU and post-discharge. The use of live biotherapeutic products (LBPs) or probiotics as additives to preterm infants have been demonstrated in multiple studies to reduce the incidence of NEC, late-onset sepsis, and all-cause mortality.
- Open Access
- 4 August 2025
- Published by MDPI AG in Preprints.org
FDA Expert Panel on Infant Formula “Operation Stork Speed” June 2025: Part 1, Nutrient Considerations
Operation Stork Speed, launched by the Food and Drug Administration(FDA) in March 2025, represents a comprehensive initiative to update infant formula regulations that have remained largely unchanged since the 1980’s. This expert panel review addresses recommendations for nutrients considering four decades of accumulated scientific evidence since then. Current FDA fatty acid regulations specify only total fat content and minimum linoleic acid requirements despite substantial international consensus on polyunsaturated fatty acid specifications. Evidence strongly supports establishing maximum linoleic acid levels and docosahexaenoic acid (DHA) and arachidonic acid (ARA) requirements, reflecting the critical role of omega-3 fatty acids in neurocognitive development and visual acuity. The panel emphasizes that saturated and monounsaturated fatty acids comprise over 80% of human milk fatty acids, while acknowledging recent concerns about seed oils and supporting balanced PUFA formulations. Carbohydrate composition presents significant concerns, as over half of US formulas contain glucose polymers (e.g. corn syrup solids) despite lactose being the primary carbohydrate energy source in human milk. Observational studies link corn syrup-based formulas to multiple possible health risks, including excess weight gain, warranting reconsideration of the value of non-lactose carbohydrate substitutions in formulas for healthy children. Protein content recommendations support decreasing the upper range of allowable intake, aligning with European standards and addressing concerns about excessive protein intake contributing to later obesity risk. Micronutrient evaluation reveals the need to reduce the iron content in routine formulas to lower levels, consistent with European Food Safety Authority recommendations and emerging safety data and a need to set upper limits for the concentration of calcium and phosphorus. Overall, infant formula is a healthy product and has many decades of successfully feeding infants. These comprehensive updates aim to more closely align US infant formula regulations with current scientific understanding and international standards while supporting optimal infant growth, development, and long-term health outcomes.
- 4 August 2025
- Published by MDPI AG in Preprints.org
Open AccessFDA Expert Panel on Infant Formula “Operation Stork Speed” June 2025: Part 1, Nutrient Considerations
Operation Stork Speed, launched by the Food and Drug Administration(FDA) in March 2025, represents a comprehensive initiative to update infant formula regulations that have remained largely unchanged since the 1980’s. This expert panel review addresses recommendations for nutrients considering four decades of accumulated scientific evidence since then. Current FDA fatty acid regulations specify only total fat content and minimum linoleic acid requirements despite substantial international consensus on polyunsaturated fatty acid specifications. Evidence strongly supports establishing maximum linoleic acid levels and docosahexaenoic acid (DHA) and arachidonic acid (ARA) requirements, reflecting the critical role of omega-3 fatty acids in neurocognitive development and visual acuity. The panel emphasizes that saturated and monounsaturated fatty acids comprise over 80% of human milk fatty acids, while acknowledging recent concerns about seed oils and supporting balanced PUFA formulations. Carbohydrate composition presents significant concerns, as over half of US formulas contain glucose polymers (e.g. corn syrup solids) despite lactose being the primary carbohydrate energy source in human milk. Observational studies link corn syrup-based formulas to multiple possible health risks, including excess weight gain, warranting reconsideration of the value of non-lactose carbohydrate substitutions in formulas for healthy children. Protein content recommendations support decreasing the upper range of allowable intake, aligning with European standards and addressing concerns about excessive protein intake contributing to later obesity risk. Micronutrient evaluation reveals the need to reduce the iron content in routine formulas to lower levels, consistent with European Food Safety Authority recommendations and emerging safety data and a need to set upper limits for the concentration of calcium and phosphorus. Overall, infant formula is a healthy product and has many decades of successfully feeding infants. These comprehensive updates aim to more closely align US infant formula regulations with current scientific understanding and international standards while supporting optimal infant growth, development, and long-term health outcomes.